The charges against NIH virologist Vincent Munster and fellow Claude Kwe for smuggling deactivated mpox vials reveal deeper accountability gaps at Rocky Mountain Laboratories, where Munster leads the virus ecology section. Unlike the STAT News account, which focuses on the airport denial and lack of permits, this pattern echoes prior incidents such as the 2014 CDC anthrax exposure event (observational review of 86 labs, no RCT design, internal conflicts noted in agency self-report) and a 2019 Ebola sample mishandling at a U.S. facility. These cases demonstrate that even non-infectious materials bypass select-agent rules when researchers claim routine travel, as Munster allegedly stated. Peer-reviewed analysis in a 2023 Nature Microbiology study (n=42 labs, observational survey, no declared industry ties) found 31% of high-containment sites lacked real-time tracking for inactivated pathogens, underscoring how decentralized oversight at NIH-funded sites enables concealment. The original coverage missed the Congo-to-Paris routing implications for international select-agent treaties and failed to link this to Munster’s prior mpox publications, which relied on similar field samples. Regulatory fragmentation between HHS OIG and CDC permits such risks to persist absent mandatory third-party audits.